[Treatment outcome of hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Hiraoka
Akira
A
D001549:Benzamides; D020544:Graft vs Leukemia Effect; D006680:HLA Antigens; D006268:Health Facilities; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality / Q000706:statistics & numerical data; D006648:Histocompatibility; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology / Q000628:therapy*; D017710:Lymphocyte Transfusion; D010879:Piperazines; D011743:Pyrimidines / Q000627:therapeutic use; D015996:Survival Rate; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D001549:Benzamides; D006680:HLA Antigens; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate